153 related articles for article (PubMed ID: 36933584)
1. Enhancement of in-vitro anti-oral cancer activities of silymarin using dispersion of nanostructured lipid carrier in mucoadhesive in-situ gel.
Shete MB; Deshpande AS; Shende P
Int J Pharm; 2023 Apr; 636():122860. PubMed ID: 36933584
[TBL] [Abstract][Full Text] [Related]
2. Nanostructured Lipid Carrier-Based Gel for Repurposing Simvastatin in Localized Treatment of Breast Cancer: Formulation Design, Development, and In Vitro and In Vivo Characterization.
Kumbhar PS; Manjappa AS; Shah RR; Nadaf SJ; Disouza JI
AAPS PharmSciTech; 2023 Apr; 24(5):106. PubMed ID: 37085596
[TBL] [Abstract][Full Text] [Related]
3. Nanostructured lipid carrier-loaded metformin hydrochloride: Design, optimization, characterization, assessment of cytotoxicity and ROS evaluation.
Shete MB; Deshpande AS; Shende PK
Chem Phys Lipids; 2023 Jan; 250():105256. PubMed ID: 36372117
[TBL] [Abstract][Full Text] [Related]
4. Lipid-based nano-formulation platform for eplerenone oral delivery as a potential treatment of chronic central serous chorioretinopathy:
Abd-Elhakeem E; El-Nabarawi M; Shamma R
Drug Deliv; 2021 Dec; 28(1):642-654. PubMed ID: 33787445
[TBL] [Abstract][Full Text] [Related]
5. Systematic implementation of quality-by-design (QbD) to develop NSAID-loaded nanostructured lipid carriers for ocular application: preformulation screening studies and statistical hybrid-design for optimization of variables.
Rathod VR; Shah DA; Dave RH
Drug Dev Ind Pharm; 2020 Mar; 46(3):443-455. PubMed ID: 32037896
[TBL] [Abstract][Full Text] [Related]
6. Formulation And Evaluation Of Nanostructured Lipid Carriers (NLCs) Of 20(S)-Protopanaxadiol (PPD) By Box-Behnken Design.
Kim MH; Kim KT; Sohn SY; Lee JY; Lee CH; Yang H; Lee BK; Lee KW; Kim DD
Int J Nanomedicine; 2019; 14():8509-8520. PubMed ID: 31749618
[TBL] [Abstract][Full Text] [Related]
7. Fabrication of nanostructured lipid carriers ocugel for enhancing Loratadine used in treatment of COVID-19 related symptoms: statistical optimization,
Abdelmonem R; Al-Samadi IEI; El Nashar RM; Jasti BR; El-Nabarawi MA
Drug Deliv; 2022 Dec; 29(1):2868-2882. PubMed ID: 36065090
[TBL] [Abstract][Full Text] [Related]
8. Optimized Nanostructured Lipid Carriers Integrated into In Situ Nasal Gel for Enhancing Brain Delivery of Flibanserin.
Fahmy UA; Ahmed OAA; Badr-Eldin SM; Aldawsari HM; Okbazghi SZ; Awan ZA; Bakhrebah MA; Alomary MN; Abdulaal WH; Medina C; Alhakamy NA
Int J Nanomedicine; 2020; 15():5253-5264. PubMed ID: 32801690
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of S(+)-zaltoprofen oral bioavailability using nanostructured lipid carrier system.
Pham TMA; Lee DH; Na YG; Jin M; Jung M; Kim HE; Yoo H; Won JH; Lee JY; Baek JS; Han SC; Lee HK; Cho CW
Arch Pharm Res; 2022 Nov; 45(11):822-835. PubMed ID: 36307644
[TBL] [Abstract][Full Text] [Related]
10. Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): An improved dermatokinetic profile for inflammatory disorder(s).
Garg NK; Sharma G; Singh B; Nirbhavane P; Tyagi RK; Shukla R; Katare OP
Int J Pharm; 2017 Jan; 517(1-2):413-431. PubMed ID: 27956192
[TBL] [Abstract][Full Text] [Related]
11. Nanostructured lipid carriers for oral delivery of silymarin: Improving its absorption and in vivo efficacy in type 2 diabetes and metabolic syndrome model.
Piazzini V; Micheli L; Luceri C; D'Ambrosio M; Cinci L; Ghelardini C; Bilia AR; Di Cesare Mannelli L; Bergonzi MC
Int J Pharm; 2019 Dec; 572():118838. PubMed ID: 31715362
[TBL] [Abstract][Full Text] [Related]
12. Combining the potential of 3D printed buccal films and nanostructured lipid carriers for personalised cannabidiol delivery.
Abdella S; Kim S; Afinjuomo F; Song Y; Upton R; Garg S
Drug Deliv Transl Res; 2024 Apr; 14(4):984-1004. PubMed ID: 37903964
[TBL] [Abstract][Full Text] [Related]
13. Development of Triamcinolone Acetonide-Loaded Nanostructured Lipid Carriers (NLCs) for Buccal Drug Delivery Using the Box-Behnken Design.
Kraisit P; Sarisuta N
Molecules; 2018 Apr; 23(4):. PubMed ID: 29690622
[TBL] [Abstract][Full Text] [Related]
14. Formulation design, characterization, and in vitro and in vivo evaluation of nanostructured lipid carriers containing a bile salt for oral delivery of gypenosides.
Yang G; Wu F; Chen M; Jin J; Wang R; Yuan Y
Int J Nanomedicine; 2019; 14():2267-2280. PubMed ID: 31015758
[TBL] [Abstract][Full Text] [Related]
15. Nanostructured Lipid Carriers for Oral Bioavailability Enhancement of Exemestane: Formulation Design, In Vitro, Ex Vivo, and In Vivo Studies.
Singh A; Neupane YR; Mangla B; Kohli K
J Pharm Sci; 2019 Oct; 108(10):3382-3395. PubMed ID: 31201904
[TBL] [Abstract][Full Text] [Related]
16. Ribociclib Nanostructured Lipid Carrier Aimed for Breast Cancer: Formulation Optimization, Attenuating
Sartaj A; Annu ; Biswas L; Verma AK; Sahoo PK; Baboota S; Ali J
Biomed Res Int; 2022; 2022():6009309. PubMed ID: 35155677
[TBL] [Abstract][Full Text] [Related]
17. Optimization of Nanostructured Lipid Carriers of Fenofibrate Using a Box-Behnken Design for Oral Bioavailability Enhancement.
Wang H; Hong W; Li X; Jin Q; Ye W; Feng Y; Huang B; Tai Z; Chen L; Li Z; Wang Y; Yang Y; Gao C; Gong W; Yang M
Curr Drug Deliv; 2022; 19(7):773-787. PubMed ID: 33902411
[TBL] [Abstract][Full Text] [Related]
18. G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol.
Qi R; Li YZ; Chen C; Cao YN; Yu MM; Xu L; He B; Jie X; Shen WW; Wang YN; van Dongen MA; Liu GQ; Banaszak Holl MM; Zhang Q; Ke X
J Control Release; 2015 Jul; 210():160-8. PubMed ID: 26003044
[TBL] [Abstract][Full Text] [Related]
19. Targeted Nanostructured Lipid Carrier for Brain Delivery of Artemisinin: Design, Preparation, Characterization, Optimization and Cell Toxicity.
Emami J; Yousefian H; Sadeghi H
J Pharm Pharm Sci; 2018; 21(1s):225s-241s. PubMed ID: 30266137
[TBL] [Abstract][Full Text] [Related]
20. Dermatokinetic assessment of luliconazole-loaded nanostructured lipid carriers (NLCs) for topical delivery: QbD-driven design, optimization, and in vitro and ex vivo evaluations.
Mahmood A; Rapalli VK; Gorantla S; Waghule T; Singhvi G
Drug Deliv Transl Res; 2022 May; 12(5):1118-1135. PubMed ID: 33895936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
